going the opposite in my mind..partnership to start. it doesnt mean you dont eventually sell the company you partner with . we have to get an application across the finish line . my guess is NASH studies may be the number one interest of the outside company The massive market and failures of other drug companies in this area offers a large company a unique opportunity to 10's of billions of dollars for one application
. they come in, fund the study and provide a huge cash infusion to the company to complete the trial and own the marketing and selling rights to the drug. Cytodyn gets a large licensing agreement along with a percentage of sales. they continue to work thru the oncology opportunities during the period . the interested partner is also going to want to see the Amarex data and what kind of shape is it in. As I mentioned before, i believe they have a 90 day NDA with an interested party in place and seeing that data is part of the analysis. i am also guessing this NDA was officially put in place around December when the decisions were made (speculating on this) to remove NP and have direct access to Dr Kelly and Recknor to work with.